TREATMENT PROTOCOL FOR ALLOVECTIN-7 IN METASTATIC CANCER BY DIRECT GENE TRANSFER

通过直接基因转移治疗转移性癌症的 ALLOVECTIN-7 方案

• 批准号: 7376318
• 负责人: PAUL O SCHWARZENBERGER
• 金额: $ 0.19万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376318
• 关键词: TREATMENT; PROTOCOL; ALLOVECTIN; METASTATIC; CANCER

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is an extended protocol to allow subjects who have participated in the Vical 301 study and have had a tumor response to continue on treatment. This study will also allow subjects who have participated on the DTIC arm only in 301 to be able to get the gene therapy product Allovectin-7. Allovectin-7 is a gene therapy product containing the gene for the HLA-B7 protein. The HLA-B7 protein causes the cells which contain it to be recognized as a foreign invader by the immune system. The HLA-B7 gene is contained within the plasmid. These plasmids will be mixed with lipids and inserted into the tumor by needle injection. Once introduced into the tumor, the cells containing the plasmid DNA produce proteins which, based on animal studies, are thought to stimulate tumor tissue refection. This research study will be conducted at multiple sites across the country and will enroll approximately 12 subjects. This treatment requires injection of the gene substance directly into the subject's tumor(s). These gene injections are thought to induce an immune response to the cancer. The use of gene therapy immunotherapeutic, Allovectin-7, may provide a less toxic, but potentially equally effective alternative to the use of rINF and rIL-2 in a chemo-biotherapy combination therapy. Even if the rate of response were not to improve using Allovectin-7, the use of this immunotherapeutic in combination with DTIC may however, either extend the time to disease progression, or produce more durable responses resulting in tangible clinical benefit to patients.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。这是一项扩展方案，允许参与Vical 301研究并出现肿瘤缓解的受试者继续接受治疗。这项研究还将允许仅在301中参与DTIC组的受试者能够获得基因治疗产品Allovectin-7。 Allovectin-7是一种含有HLA-B7蛋白基因的基因治疗产品。HLA-B7蛋白导致含有它的细胞被免疫系统识别为外来入侵者。HLA-B7基因包含在质粒内。这些质粒将与脂质混合，并通过针头注射插入肿瘤中。一旦被引入肿瘤，含有质粒DNA的细胞产生蛋白质，基于动物研究，这些蛋白质被认为刺激肿瘤组织反射。本研究将在全国多个研究中心进行，将入组约12例受试者。这种治疗需要将基因物质直接注射到受试者的肿瘤中。这些基因注射被认为会诱导对癌症的免疫反应。 基因治疗免疫抑制剂Allovectin-7的使用可以提供毒性较小但与在化学-生物疗法组合疗法中使用rINF和rIL-2潜在地同等有效的替代方案。即使使用Allovectin-7的应答率没有改善，但是这种免疫抑制剂与DTIC组合的使用可以延长疾病进展的时间，或者产生更持久的应答，从而对患者产生切实的临床益处。